Newer Potential Pharmacological Targets for Multiple Sclerosis
Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS...
Saved in:
Published in | Journal of pharmaceutical sciences and research Vol. 12; no. 2; pp. 302 - 304 |
---|---|
Main Authors | , |
Format | Journal Article |
Language | English |
Published |
Cuddalore
Journal of Pharmaceutical Sciences and Research
01.02.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS), the most prevalent neurological disability, is an autoimmune-mediated disorder that affects the central nervous system (CNS) and often leads to severe physical or cognitive incapacitation as well as neurological problems in young adult Multifocal zones of inflammation due to focal T-lymphocytic and macrophage infiltrations, and oligodendrocyte death are the primary causes of myelin sheath de- struction that result in the formation of CNS plaques composed of inflammatory cells and their products, demyelinated and transected axons, and astrogliosis in both white and gray matter. Discontinuation of NTZ (usually for safety concerns, due to a high risk of progressive multifocal leukoencephalopathy) is still a dramatic moment in MS therapeutic management and no guidelines exist about the ideal exit strategy. [...]the choice of CD20-depleting agents which reduce the high number of circulating B-cells could be useful. Tight junctions are the critical component of the BCNSB as they control paracellular diffusion and maintain the structural and functional polarity of the specialized endothelial cells of the BBB and BSCB. [...]the BCNSB contributes to the homeostasis of the parenchyma of the brain and spinal cord and provides protection against many toxic compounds and pathogens Indeed, the BCNSB is largely impermeable to compounds that |
---|---|
AbstractList | Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly targeting no evidence of disease activity. (1)This can make it hard for your brain to send signals to the rest of your body.Multiple sclerosis (MS), the most prevalent neurological disability, is an autoimmune-mediated disorder that affects the central nervous system (CNS) and often leads to severe physical or cognitive incapacitation as well as neurological problems in young adult Multifocal zones of inflammation due to focal T-lymphocytic and macrophage infiltrations, and oligodendrocyte death are the primary causes of myelin sheath de- struction that result in the formation of CNS plaques composed of inflammatory cells and their products, demyelinated and transected axons, and astrogliosis in both white and gray matter. Discontinuation of NTZ (usually for safety concerns, due to a high risk of progressive multifocal leukoencephalopathy) is still a dramatic moment in MS therapeutic management and no guidelines exist about the ideal exit strategy. [...]the choice of CD20-depleting agents which reduce the high number of circulating B-cells could be useful. Tight junctions are the critical component of the BCNSB as they control paracellular diffusion and maintain the structural and functional polarity of the specialized endothelial cells of the BBB and BSCB. [...]the BCNSB contributes to the homeostasis of the parenchyma of the brain and spinal cord and provides protection against many toxic compounds and pathogens Indeed, the BCNSB is largely impermeable to compounds that |
Author | Harikrishnan, N Gejalakshmi, S |
Author_xml | – sequence: 1 givenname: S surname: Gejalakshmi fullname: Gejalakshmi, S – sequence: 2 givenname: N surname: Harikrishnan fullname: Harikrishnan, N |
BookMark | eNqNisEKgkAURYcoyMp_GGgtmKNjbtpE0aYQdC-DPG1kmmdvRvr9XPQB3c3hcO6GLS1aWLAgLvIsOqRZsWahc0M8TyRHmYqAnR7wAeIlerBeK8PLp6KXatFgr9vZa0U9eMc7JH6fjNejAV61Bgiddju26pRxEP64ZfvrpT7fopHwPYHzzYAT2Tk1icillJkQsfjv9QU0VDp5 |
ContentType | Journal Article |
Copyright | Copyright Journal of Pharmaceutical Sciences and Research Feb 2020 |
Copyright_xml | – notice: Copyright Journal of Pharmaceutical Sciences and Research Feb 2020 |
DBID | 04Q 04S 04W 3V. 7X7 7XB 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH K9. M0S PQEST PQQKQ PQUKI PRINS |
DatabaseName | India Database India Database: Business India Database: Science & Technology ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China |
DatabaseTitle | ProQuest Indian Journals ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Indian Journals: Business Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) Indian Journals: Science & Technology ProQuest One Academic ProQuest Central (Alumni) |
DatabaseTitleList | ProQuest Indian Journals |
Database_xml | – sequence: 1 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 0975-1459 |
EndPage | 304 |
GroupedDBID | --- 04Q 04S 04W 3V. 7X7 7XB 8AO 8FI 8FJ 8FK 8R4 8R5 ABUWG ADBBV AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS BAWUL BENPR BPHCQ BVXVI CCPQU DIK FRP FYUFA HMCUK K9. PQEST PQQKQ PQUKI PRINS PROAC Q2X RXW UKHRP W2D |
ID | FETCH-proquest_journals_23766653303 |
IEDL.DBID | 7X7 |
IngestDate | Thu Oct 10 20:11:26 EDT 2024 |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-proquest_journals_23766653303 |
PQID | 2376665330 |
PQPubID | 54977 |
ParticipantIDs | proquest_journals_2376665330 |
PublicationCentury | 2000 |
PublicationDate | 20200201 |
PublicationDateYYYYMMDD | 2020-02-01 |
PublicationDate_xml | – month: 02 year: 2020 text: 20200201 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cuddalore |
PublicationPlace_xml | – name: Cuddalore |
PublicationTitle | Journal of pharmaceutical sciences and research |
PublicationYear | 2020 |
Publisher | Journal of Pharmaceutical Sciences and Research |
Publisher_xml | – name: Journal of Pharmaceutical Sciences and Research |
SSID | ssj0000328643 |
Score | 4.290711 |
Snippet | Early initiation of treatment has delayed the onset of disability progression. [...]there is increased interest in treating to target in MS, particularly... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | 302 |
SubjectTerms | Blood-brain barrier Immune system Immunology Inflammation Memory Multiple sclerosis Nervous system Pathogenesis Proteins Spinal cord Young adults |
Title | Newer Potential Pharmacological Targets for Multiple Sclerosis |
URI | https://www.proquest.com/docview/2376665330 |
Volume | 12 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED90e_FF_MSPOQLKnlZs0yxZXyYqG0NwFK3Qt5EuKfjS6lof9t8vl2VWfNjzwSW5hLvL5Xe_ANxJTWWmWOhJoajHBj7zhipneJa5klxxmlm2zxmffrCXdJC6glvlYJVbn2gdtSoXWCO_R_QG54iFfPj69vDXKHxddV9o7EM7oD5HSJdIxW-NBbniOPbj_HOzNnZMjuDQJX3kcbNLx7CnixPoxRvW6FWfJE0TVNUnPRI3fNKrUxgZR6SXJC5rRPYYPX_EaGKSWDR3RUz-SV4dQJC8m5FMBPyszuB2Mk6ep952dnN3fqp5s9rwHFpFWegLICxi_oKzYIikQZEIs4jmUuQyoBoTJ30JnV2arnaLr-GA4l3SIpI70KqXP_rGBNw661qrdqH9NJ7Fb2v9Oor6 |
link.rule.ids | 315,783,787,12068,21400,31731,33756,43322,43817,74073,74630 |
linkProvider | ProQuest |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQSUw1SkxKMTHWTTRPMdI1MTUw0bVISTMBpWWzlESzFDOjJPBpn35mHqEmXhGmEdABt2LoskpYmQguqFPyk0Fj5Pqg1RtmZqC1kPYFhbqgW6NAs6vQKzSYGVhB53CBbjAwjzCHj7GAzoozA-3HQStmwXWHmyADP7TRp-AIiSUhBqbUPGEGtQDIqdGVOgohiE1QxToKagoBiPOkK0UY7IAFUWqRQkB-CWhlD9AcJGlQECuEgFdzFysA258KvtAFggrBQJuANWBmsSiDsptriLOHLsx18dD0UxyP8K2xGANLXn5eqgSDgomliUGymYmhBejQIEtz4yRLo7RE87REQ6NUUMMpVZJBBp9JUvil5Rk4PUJ8feJ9PP28pRm4jED9SvDqZBkGlpKi0lRZYOVbkiQHDmEAO7uMRw |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfZ3PS8MwFMcfOkG8iD_xx9SAstPKtjRL1osiapm_RsEKvZV0ScFLq2s97L83L8useNg5kCavj_dekk--AbiSmspMMd-TQlGPDfvMG6mcoS9zJbniNLNqnxM-fmdPyTBx_FPlsMplTLSBWpVT3CPvIb3BObKQvdxhEdF9ePP55eELUnjS6p7TWIcNYVYp6PMiEb_7Lagbx_Fuzr-Qa_NIuAPbrgAkt4s_tgtrutiDTrRQkJ53SdxciKq6pEOiRlt6vg_XJijpGYnKGikf08-fZjQ3iS3ZXRFTi5JXBwuSN_Mlkw0_qgO4DB_iu7G3HF3qfKlKm5n7h9AqykIfAWEB6085G4xQQCgQfhbQXIpcDqjGIkofQ3tVTyermy9g0xg3fXmcPJ_CFsUlpgWV29CqZ9_6zOThOju3Bv4B-3uQfw |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Newer+Potential+Pharmacological+Targets+for+Multiple+Sclerosis&rft.jtitle=Journal+of+pharmaceutical+sciences+and+research&rft.au=Gejalakshmi%2C+S&rft.au=Harikrishnan%2C+N&rft.date=2020-02-01&rft.pub=Journal+of+Pharmaceutical+Sciences+and+Research&rft.eissn=0975-1459&rft.volume=12&rft.issue=2&rft.spage=302&rft.epage=304&rft.externalDBID=HAS_PDF_LINK |